These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 8665545)

  • 1. A longitudinal study of the effects of an L-dopa drug holiday on the course of Parkinson's disease.
    Corona T; Rivera C; Otero E; Stopp L
    Clin Neuropharmacol; 1995 Aug; 18(4):325-32. PubMed ID: 8665545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease.
    Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B
    Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parkinson's disease: follow-up after "drug holiday".
    Feldman RG; Kaye JA; Lannon MC
    J Clin Pharmacol; 1986; 26(8):662-7. PubMed ID: 3793959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Four pioneers of L-dopa treatment: Arvid Carlsson, Oleh Hornykiewicz, George Cotzias, and Melvin Yahr.
    Lees AJ; Tolosa E; Olanow CW
    Mov Disord; 2015 Jan; 30(1):19-36. PubMed ID: 25488030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response of non-motor symptoms to levodopa in late-stage Parkinson's disease: Results of a levodopa challenge test.
    Fabbri M; Coelho M; Guedes LC; Chendo I; Sousa C; Rosa MM; Abreu D; Costa N; Godinho C; Antonini A; Ferreira JJ
    Parkinsonism Relat Disord; 2017 Jun; 39():37-43. PubMed ID: 28389156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Levodopa "drug holiday" with amantadine infusions as a treatment of complications in Parkinson's disease.
    Koziorowski D; Friedman A
    Mov Disord; 2007 May; 22(7):1033-6. PubMed ID: 17370308
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
    Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study.
    Przuntek H; Welzel D; Gerlach M; Blümner E; Danielczyk W; Kaiser HJ; Kraus PH; Letzel H; Riederer P; Uberla K
    J Neural Transm (Vienna); 1996; 103(6):699-715. PubMed ID: 8836932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued.
    Przuntek H; Welzel D; Blümner E; Danielczyk W; Letzel H; Kaiser HJ; Kraus PH; Riederer P; Schwarzmann D; Wolf H
    Eur J Clin Pharmacol; 1992; 43(4):357-63. PubMed ID: 1451713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The results of drug holiday in Parkinson's disease].
    Martínez F; Castillo J; Castro A; Lema M; Noya M
    Neurologia; 1992 Nov; 7(9):254-9. PubMed ID: 1445710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is L-DOPA drug holiday useful?
    Direnfeld LK; Feldman RG; Alexander MP; Kelly-Hayes M
    Neurology; 1980 Jul; 30(7 Pt 1):785-8. PubMed ID: 7190248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relation of serum uric acid levels with L-Dopa treatment and progression in patients with Parkinson's disease.
    Vieru E; Köksal A; Mutluay B; Dirican AC; Altunkaynak Y; Baybas S
    Neurol Sci; 2016 May; 37(5):743-7. PubMed ID: 26753800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An analysis of long-term L-dopa therapy in 122 cases of Parkinson's disease over 14 years--when should L-dopa therapy be initiated?
    Indo T; Takahashi A
    Jpn J Med; 1986 May; 25(2):114-21. PubMed ID: 3747258
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
    Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
    Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of standardized extract of Trigonella foenum-graecum L seeds as an adjuvant to L-Dopa in the management of patients with Parkinson's disease.
    Nathan J; Panjwani S; Mohan V; Joshi V; Thakurdesai PA
    Phytother Res; 2014 Feb; 28(2):172-8. PubMed ID: 23512705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Head-to-Head Comparison of the Neuropsychiatric Effect of Dopamine Agonists in Parkinson's Disease: A Prospective, Cross-Sectional Study in Non-demented Patients.
    Pérez-Pérez J; Pagonabarraga J; Martínez-Horta S; Fernández-Bobadilla R; Sierra S; Pascual-Sedano B; Gironell A; Kulisevsky J
    Drugs Aging; 2015 May; 32(5):401-7. PubMed ID: 25941103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of piribedil in early combination with L-dopa in the treatment of Parkinson's disease: a 6-month open study.
    Suwantamee J; Nidhinandana S; Srisuwananukorn S; Laptikultham S; Pisarnpong A; Chankrachang S; Bundhukul A
    J Med Assoc Thai; 2004 Nov; 87(11):1293-300. PubMed ID: 15825702
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and pharmacokinetic evaluation of L-dopa and cabergoline cotreatment in Parkinson's disease.
    Del Dotto P; Colzi A; Musatti E; Strolin Benedetti M; Persiani S; Fariello R; Bonuccelli U
    Clin Neuropharmacol; 1997 Oct; 20(5):455-65. PubMed ID: 9331523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.